Endothelial PAS domain-containing protein 1 inhibitors - Pipeline Insight, 2024

This “Endothelial PAS domain-containing protein 1 inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Endothelial PAS domain-containing protein 1 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Endothelial PAS domain-containing protein 1 inhibitors Understanding

Endothelial PAS domain-containing protein 1 inhibitors: Overview

Endothelial PAS domain-containing protein 1 (EPAS1, also known as hypoxia-inducible factor-2alpha (HIF-2alpha)) is a protein that is encoded by the EPAS1 gene in mammals. It is a type of hypoxia-inducible factor, a group of transcription factors involved in the physiological response to oxygen concentration. The gene is active under hypoxic conditions. It is also important in the development of the heart, and for maintaining the catecholamine balance required for protection of the heart. Mutation often leads to neuroendocrine tumors. This gene encodes a transcription factor involved in the induction of genes regulated by oxygen, which is induced as oxygen levels fall. The encoded protein contains a basic-helix-loop-helix domain protein dimerization domain as well as a domain found in proteins in signal transduction pathways which respond to oxygen levels. Mutations in this gene are associated with erythrocytosis familial type 4. Several drugs inhibiting EPAS1 are under clinical trials to treat several indications including renal cell carcinoma and glioblastoma.

Endothelial PAS domain-containing protein 1 inhibitors - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Endothelial PAS domain-containing protein 1 inhibitors pipeline landscape is provided which includes the disease overview and Endothelial PAS domain-containing protein 1 inhibitors treatment guidelines. The assessment part of the report embraces, in depth Endothelial PAS domain-containing protein 1 inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Endothelial PAS domain-containing protein 1 inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Endothelial PAS domain-containing protein 1 inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Endothelial PAS domain-containing protein 1 inhibitors.

Endothelial PAS domain-containing protein 1 inhibitors Emerging Drugs Chapters

This segment of the Endothelial PAS domain-containing protein 1 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Endothelial PAS domain-containing protein 1 inhibitors Emerging Drugs

Belzutifan: Merck & Co.,Belzutifan (previously PT2977 and MK-6482) binds to and inhibits HIF-2a function, and has been developed as a novel cancer therapeutic. HIF-2a is a transcription factor component that is established as an oncogneic driver of cc RCC, via loss of its interaction with the tumour suppressor von Hippel-Lindau (VHL), which results in disrupted proteasomal degradation and thereby accumulation of HIF-2a. Belzutifan received FDA approval for the treatment of select VHL-associated cancers on August 13, 2021. It is currently being evaluated in Phase III stage of development for the treatment of Renal cell carcinoma and in Phase II trial to treat Biliary cancer; Colorectal cancer; Livercancer.

PT2385: Peloton Therapeutics PT2385 is the first clinical stage antagonist of hypoxia inducible factor-2a (HIF-2a), a transcription factor implicated in the development and progression of renal cancer. It is currently being evaluated in Phase II clinical trials to treat glioblastoma and renal cell carcinoma. In May 2019, Merck and Peloton therapeutics have entered into a definitive agreement under which Merck, through a subsidiary, will acquire privately held Peloton, a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2a (HIF-2a) for the treatment of patients with cancer and other non-oncology diseases.

Endothelial PAS domain-containing protein 1 inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Endothelial PAS domain-containing protein 1 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Endothelial PAS domain-containing protein 1 inhibitors

There are approx. 7+ key companies which are developing the therapies for Endothelial PAS domain-containing protein 1 inhibitors. The companies which have their Endothelial PAS domain-containing protein 1 inhibitors drug candidates in the most advanced stage, i.e. phase III include Merck & Co,.

Phases

This report covers around 7+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Endothelial PAS domain-containing protein 1 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Endothelial PAS domain-containing protein 1 inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Endothelial PAS domain-containing protein 1 inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Endothelial PAS domain-containing protein 1 inhibitors drugs.

Endothelial PAS domain-containing protein 1 inhibitors Report Insights

• Endothelial PAS domain-containing protein 1 inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Endothelial PAS domain-containing protein 1 inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Endothelial PAS domain-containing protein 1 inhibitors drugs?
• How many Endothelial PAS domain-containing protein 1 inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Endothelial PAS domain-containing protein 1 inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Endothelial PAS domain-containing protein 1 inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Endothelial PAS domain-containing protein 1 inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 2 business days.